RSNA: TeraRecon boosts mobile options

TriMed Staff | | Health Exec | Digital Transformation
TeraRecon highlighted mobility and flexibility, showcasing Aquarius Mobile and iNstance Launch licensing at the 96th meeting of the Radiological Society of North America (RSNA) held in Chicago, Nov. 28 to Dec. 2.

Mobile iNtuition is available for the iPhone, iPad and iPod Touch via a download of the Aquarius Mobile application from the Apple App Store. Android is supported via a browser, which can be accessed via TeraRecon’s web site.

Foster City, Calif.-based TeraRecon also demonstrated the iNstance Launch Licensing option for iNtuition Unlimited. The new licensing option allows a customer to buy the necessary hardware and professional services to set up and train the system, and then pay for actual system use, similar to a cell phone plan. This new model is designed to make the full iNtuition suite available with unlimited concurrent users and unlimited capacity.

TriMed Staff

Related Content

From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI
Healthcare-specific AI: How to multiply successes and head off accidents

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.